Drug Profile
INX 4437
Alternative Names: INXC 4437Latest Information Update: 17 Jun 2002
Price :
$50
*
At a glance
- Originator Inex Pharmaceuticals Corporation
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Insulin-like growth factor I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jun 2002 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 28 May 2001 No-Development-Reported for Cancer in Canada (Unknown route)
- 29 Oct 1998 New profile